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ase error at the nucleotide site bearing the mutation. In
targeted NGS, synthetic competitive IS control for sto-
chastic sampling at input of both target into library
preparation and of target library product into sequencer,
enable reduced sequencing space requirement, and con-
trol for qualitative errors generated during library
preparation and sequencing. These controls enable ac-
curate clinical diagnostic reporting of conﬁdence limits
and limit of detection for copy number measurement, and
reduce sequencing space required for analysis.Characteristics, oncogene dependency,
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Lung cancer is molecularly heterogeneous characterized
by various genetic alterations. Many targetable mutations
in lung adenocarcinoma occur at low frequencies, which
limits timely recruitment of patients in clinical trials of
precision therapy. Thus, preclinical animal models are
invaluable for evaluation of novel targeted drugs.
Recurrent RET fusions have been found in 1-2% of non-
small cell lung cancer (NSCLC). Among them KIF5B-RET
fusion is the most prevalent. To develop an animal model
for evaluation of KIF5B-RET fusion in lung adenocarci-
noma, we generated transgenic mice containing a doxy-
cycline-inducible tetO-KIF5B-RET transgene. Induction of
CCSP-rtTA/tetO-KIF5B-RET bitransgenic mice with
doxycycline resulted in MRI- and CT-detectable lung
adenocarcinoma in 4-5 months. KIF5B-RET-induced lung
adenocarcinoma is characterized by desmoplastic reac-
tion. Desmoplasia is associated with invasive lung
adenocarcinoma and is found in human RET-fusion-pos-
itive lung adenocarcinoma, but it has not been observed
in transgenic mouse models of EGFRL858R-, KrasG12D-, or
PTPN11E76K-induced lung adenocarcinoma. Using MRI,
CT, and histological examinations, we evaluated onco-
gene dependence and the response to the multikinase
RET inhibitor ponatinib in KIF5B-RET-induced lung tu-
mors. Tumors regressed one month after Dox withdrawal
or ponatinib treatment. Thus, we have established a
transgenic mouse model of KIF5B-RET-induced lung
adenocarcinoma. The KIF5B-RET-induced lung tumorsare associated with desmoplasia, dependent on KIF5B-
RET for maintaining the malignant phenotype, and
respond to ponatinib treatment.
Mechanism of Notch and Sox2 in
Kras driven lung adenocarcinoma
in type II cells*
Xia Xu, Rishi Rampersad, Brigid L.M. Hogan,
Mark W. Onaitis Duke University, Durham, NCWe have previously used cell lineage speciﬁc CreER mouse
models to identify Type II cells as the cell-of-origin of
KrasG12D induced lung adenocarcinoma.Using gain and loss
of function genetic models, we discovered the active Notch
signaling and low Sox2 dictate the ability of type II cells to
proliferate and progress into adenocarcinoma upon
KrasG12Dactivation.Hereweprovided further evidence that
Notch signaling is required for KrasG12D induced Type II
cells into a biopotent embryonic state. These SpcþRageþ
cells express speciﬁc lung embryonic development marker
Sox9 and Ezh2. Additionally, genetical and chemical Sox2
upregulation profoundly inhibits KrasG12D-induced lung
tumor formation inType II cells. Sox2-expressingType II cells
are unable to dedifferentiating Type II cells when Kras is
activated. Inconclusion,ourdatasuggestKrascanspeciﬁcally
transform Type II cells into lung adenocarcinoma by dedif-
ferentiating Type II cells into SpcþRageþ bipotent embry-
onic progenitor cells through activated Notch signaling.
Unregulated Sox2 can alter Type II cells to proximal cell state,
with subsequent loss of ability to dedifferentiate into these
bipotent embryonic cells. Our ﬁndings could provide a new
therapeutic strategy to target Kras activated lung cancer.ROR1 functions as a scaffold of
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February 2016 Abstracts S55Emerging evidence, though currently sparse, suggests
that “lineage-speciﬁc transcription factors” with devel-
opmental roles in normal progenitor cells of particular
lineages may also confer dependency for survival to
certain types of cancer cells. We previously reported
that TTF-1/NKX2-1, a homeobox-containing transcrip-
tion factor indispensable for lung morphogenesis, plays
a role as a “lineage-survival” oncogene in lung adeno-
carcinoma1. Despite the requirement of sustained
NKX2-1/TTF-1 expression in survival of lung
adenocarcinoma cells, NKX2-1/TTF-1 itself cannot be
considered as a molecular target for treatment of this
devastating cancer, because of its indispensable roles
in normal lung physiology, such as production and
secretion of surfactant proteins2. Thus, elucidation of
how NKX2-1/TTF-1 mediates survival signals has long
been anticipated. In this regard, we have found that
TTF-1 induces expression of the receptor tyrosine
kinase-like orphan receptor 1 (ROR1), which in turn
sustains a favorable balance between prosurvival
PI3K-AKT and proapoptotic p38 signaling in both
ROR1 kinase activity-dependent and -independent
manner3. While alterations in EGFR signaling are
involved as a “driver” in lung adenocarcinoma
pathogenesis, ROR1 appears to play a “sustainer role”
for the EGFR-mediated signaling. Interestingly, we
also observed that ROR1 knockdown effectively
overcame EGFR-TKI resistance-conferring, HGF-
mediated bypass signaling through MET, suggesting
that ROR1 sustains not only EGFR but also additional
RTK signaling. However, the underlying mechanism
remained rather elusive.We report here an unanticipated function of this re-
ceptor tyrosine kinase (RTK) as a scaffold of cavin-1 and
caveolin-1 (CAV1), two essential structural components
of caveolae. Caveolae are 50-100 nm invaginations of the
plasma membrane that play various physiological roles,
including function as a platform for insulin-induced
signaling in adipose tissue. We found that ROR1 facili-
tates the interactions of cavin-1 and CAV1 at the plasma
membrane in a kinase-independent manner, thereby
preventing the lysosomal degradation of CAV1. Caveolae
structures and prosurvival signaling towards AKT
through multiple RTKs are consequently sustained.
These ﬁndings provide mechanistic insight into how
ROR1 inhibition can overcome EGFR-TKI resistance due
to bypass signaling via diverse RTKs such as MET and
IGF-IR, which is currently a major clinical obstacle.
Considering its onco-embryonic expression, inhibition of
the scaffold function of ROR1 in patients with lung
adenocarcinoma is an attractive approach for improved
treatment of this devastating cancer.
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